Related Experiment Video
Updated: Feb 20, 2026
10:31
Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
746
Effects of incretin-based therapies on renal function
Vasilis Tsimihodimos1, Moses Elisaf1
1Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece.
European Journal of Pharmacology
|October 26, 2017
Summary
Incretin-based therapies, including GLP-1 receptor agonists and DPP-IV inhibitors, impact kidney function through multiple pathways. This review examines their clinical significance for renal health in diabetes management.
Area of Science:
- Endocrinology
- Nephrology
- Pharmacology
Background:
- Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-IV inhibitors are widely used antidiabetic medications.
- These incretin-based therapies activate glucagon-like peptide-1 receptors, influencing carbohydrate metabolism.
- Emerging evidence indicates effects on renal function via both receptor-dependent and independent mechanisms.
Purpose of the Study:
- To review preclinical and clinical data on the renal effects of incretin-based therapies.
- To discuss the clinical significance of these therapies for kidney function in diabetic patients.
Main Methods:
- Systematic review of existing literature.
- Analysis of preclinical studies investigating mechanisms of action.
- Evaluation of clinical trials and observational studies on renal outcomes.
Main Results:
- Incretin-based therapies demonstrate multifaceted effects on renal function.
- Both GLP-1 receptor agonists and DPP-IV inhibitors show potential renoprotective effects.
- The precise clinical impact on renal indices requires further elucidation.
Conclusions:
- Incretin-based therapies may offer benefits for renal function in diabetic individuals.
- Further research is needed to definitively establish their role in clinical practice for kidney protection.
- Understanding these effects is crucial for optimizing diabetes and kidney disease management.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
752
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
752
01:24Glucagon-like Receptor Agonists
1.0K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.0K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
702
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
702
01:06Oral Hypoglycemic Agents: Glinides
715
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
715
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
615
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
615
01:17Oral Hypoglycemic Agents: Sulfonylureas
1.3K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.3K